Clinical Trials Directory

Trials / Terminated

TerminatedNCT00002934

Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ

Local Excision Alone for Selected Patients With DCIS of the Breast

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
711 (actual)
Sponsor
Eastern Cooperative Oncology Group · Network
Sex
Female
Age
18 Years – 120 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: The evaluation of breast cancer recurrence rates may improve the ability to plan cancer treatment for patients with breast cancer. PURPOSE: Study to evaluate the rate of recurrence of breast cancer in women who have had surgery for ductal carcinoma in situ.

Detailed description

OBJECTIVES: * Evaluate actuarial local in situ and invasive recurrence rates at 5 and 10 years after local excision in women with a favorable ductal carcinoma in situ (DCIS) prognosis. * Evaluate concordance between institutional pathologists and central review pathologists with respect to diagnosis and grading of DCIS. * Identify parameters that indicate increased or decreased risk of recurrence in the absence of irradiation. * Evaluate patterns of salvage of recurrence and rates of breast conservation. * Evaluate actuarial relapse-free, overall, and cause-specific survival at 5 and 10 years post DCIS excision. OUTLINE: This is a registration study stratified by histologic grade (high vs low or intermediate) and adjuvant tamoxifen therapy (yes vs no). Patients receive standard clinical and mammographic follow-up for greater than 10 years. If recurrence occurs, treatment will be at the discretion of the investigators. Patients may receive adjuvant oral tamoxifen daily for 5 years after local excision. A follow up magnification view mammogram must be taken after the last local excision, and microcalcification must be negative. Patients are followed every 6 months for the first 10 years, and then annually thereafter. PROJECTED ACCRUAL: 1000 (500 per stratum) eligible and evaluable patients will be enrolled at an estimated accrual rate of 250 patients per year.

Conditions

Interventions

TypeNameDescription
PROCEDURElong-term screening

Timeline

Start date
1997-06-25
Primary completion
2007-12-01
Completion
2012-10-01
First posted
2003-04-16
Last updated
2023-06-22

Locations

30 sites across 2 countries: United States, South Africa

Source: ClinicalTrials.gov record NCT00002934. Inclusion in this directory is not an endorsement.